Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil
Source abstract
Abstract
The aim of the present work is to formulate heparin-modified-polycaprolactone (HEP) core shell nanoparticles (NPs) of 5-fluorouracil (5-FU). These NPs were characterized for various in vitro parameters like particle size, zeta potential, etc. HEP NPs were found to maintain comparatively slower drug release pattern (98.9% in 96 h) than PCL NPs. Cytotoxicity studies demonstrated a massive cytotoxic potential of 5-FU-loaded HEP NPs in A549, MDA-MD-435, and SK-OV-3 cancer cell lines. Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Cancer Treatment and Pharmacology · Colorectal Cancer Treatments and Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, Drug Delivery and Nanotechnology Laboratories, Guru Ramdas Khalsa Institute of Science and Technology, Pharmacy, Jabalpur, India;
Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour Vishwavidyalaya, Sagar, Madhya Pradesh, India;
Nanotechnology Project Laboratories, Department of Pharmaceutics, Bhagyoday Tirth Pharmacy College, Sagar, Madhya Pradesh, India
Funding
MPCST, Bhopal
References (36)
Show source-provided references
1. 10.3109/10837450.2013.86055110.3109/10837450.2013.860551 ↗
2. 10.2174/1573413711309666011910.2174/15734137113096660119 ↗
3. 10.1016/S1773-2247(14)50088-310.1016/S1773-2247(14)50088-3 ↗
4. 10.1038/nrc90310.1038/nrc903 ↗
5. 10.1016/j.jchromb.2004.01.04310.1016/j.jchromb.2004.01.043 ↗
6. 10.1001/jama.1962.0305030001500310.1001/jama.1962.03050300015003 ↗
7. 10.1038/nmat299210.1038/nmat2992 ↗
8. Boyle P, Levin B. 2008. World Cancer Report. World Health Organization Press.
9. 10.1590/S1984-8250201300010001310.1590/S1984-82502013000100013 ↗
10. 10.1046/j.1365-2710.1998.00177.x10.1046/j.1365-2710.1998.00177.x ↗
11. 10.2165/00003088-198916040-0000210.2165/00003088-198916040-00002 ↗
12. 10.1021/ac900043y10.1021/ac900043y ↗
13. 10.3109/10717544.2014.97851210.3109/10717544.2014.978512 ↗
14. 10.1016/S0006-2952(97)00040-310.1016/S0006-2952(97)00040-3 ↗
15. 10.1056/NEJM19910530324220610.1056/NEJM199105303242206 ↗
16. Hu Z, Xia X, Tang L. 2004. Process for synthesizing oil and surfactant-free hyaluronic acid nanoparticles and microparticles. US Patent App. 20,060/040,892.
17. 10.3322/caac.2007310.3322/caac.20073 ↗
18. 10.1016/S0378-5173(03)00225-410.1016/S0378-5173(03)00225-4 ↗
19. 10.1016/j.carbpol.2011.06.02410.1016/j.carbpol.2011.06.024 ↗
20. 10.1126/scisignal.200591610.1126/scisignal.2005916 ↗
21. 10.1007/s12034-008-0016-210.1007/s12034-008-0016-2 ↗
22. 10.1038/sj.bjc.660030710.1038/sj.bjc.6600307 ↗
23. 10.1021/la048646i10.1021/la048646i ↗
24. 10.1016/j.ijpharm.2004.11.01010.1016/j.ijpharm.2004.11.010 ↗
25. 10.1016/S0168-3659(99)00012-710.1016/S0168-3659(99)00012-7 ↗
26. 10.1016/j.molliq.2015.06.06910.1016/j.molliq.2015.06.069 ↗
27. 10.1016/j.molliq.2014.10.01310.1016/j.molliq.2014.10.013 ↗
28. 10.3109/10717544.2013.86855710.3109/10717544.2013.868557 ↗
29. 10.1023/A:102267670956510.1023/A:1022676709565 ↗
30. 10.1111/j.1742-4658.2010.07800.x10.1111/j.1742-4658.2010.07800.x ↗
31. 10.1016/j.porgcoat.2011.10.00410.1016/j.porgcoat.2011.10.004 ↗
32. Xie J, Hwa Wang C. 2004. Paclitaxel-loaded biodegradable nanoparticles developed by direct dialysis and electrodydrodynamic atomization methods. AIChE Annual Meeting, Texas; 7–12.
33. 10.1166/jbn.2010.111810.1166/jbn.2010.1118 ↗
34. 10.1080/1061186080209549410.1080/10611860802095494 ↗
35. 10.1016/j.nano.2007.09.00410.1016/j.nano.2007.09.004 ↗
36. 10.1016/j.canlet.2003.11.03710.1016/j.canlet.2003.11.037 ↗